22.03.2023
Interim decision concerning suspension of establishment licences and medicinal product authorisations of Amino AG
01.03.2023
Regulations on the use of QR codes on packaging and in medicinal product information
24.02.2023
16,855 reports of suspected adverse vaccination reactions evaluated
13.02.2023
Swissmedic launches the public consultation on Guideline M13 of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH Guidelines), with a deadline of 26 May 2023 for comments
10.02.2023
Number of illegally imported therapeutic products has decreased
26.01.2023
Raimund Bruhin (Executive Director, Swissmedic) and Gavin Hall (Deputy CEO, Veterinary Medicines Directorate) have signed a Memorandum of Understanding on collaboration in the area of veterinary medicinal products.
13.01.2023
Information for professionals, updating the communication dated 14 December 2022 on key aspects connected with the suspension of the establishment licences and authorisations of the companies Amino AG and Dr. Heinz Welti AG
10.01.2023
Increase in illegal imports of nasal sprays and laxatives
01.01.2023
Section 5, Clinical Assessment, of the Public Assessment Report is not part of the SwissPAR
14.12.2022
Medicinal products that have already been delivered can still be distributed
13.12.2022
Suspected adverse reactions can be reported electronically
09.12.2022
Swissmedic guarantees efficient, independent therapeutic products oversight
02.12.2022
Eingabefrist: 20. Januar 2023
01.12.2022
Temporary additional indications will also be possible from 1 January 2023
01.12.2022
Publication of the revised specification documents and forms
30.11.2022
Excellent Progress by ICH Expert Working Groups in Incheon, Republic of Korea
25.11.2022
16,212 reports of suspected adverse vaccination reactions evaluated
21.11.2022
Access Consortium commits to demonstrate greater inspection reliance and accept GMP inspection outcomes held amongst their members
10.11.2022
Successful Swissmedic online event on 3 November 2022
07.11.2022
Swissmedic is issuing an urgent warning regarding slimming products and other supposedly natural products
02.11.2022
risks currently being investigated
10.10.2022
Comirnaty Bivalent Original / Omicron BA.1 (tozinameran / riltozinameran) from Pfizer authorised from age 18
22.09.2022
Application submitted for Comirnaty Original/Omicron BA.4-5
14.09.2022
Regulatory and scientific developments regarding nitrosamines/Update September 2022
02.09.2022
Swissmedic authorises indication extension and booster
02.09.2022
Swissmedic reviews Pfizer Schweiz AG application for Comirnaty®
01.09.2022
Clarification of safety-relevant updates to medicinal product information for authorisations according to Art. 14 para. 1 let. abis TPA